REDWOOD CITY, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, announced that researchers at Rockyview General Hospital are using the company’s biometric device in a study designed to identify early warning sign for illness and to promote over-all wellness.
Researchers at Rockyview General Hospital (RGH), a large 650 bed hospital which is administered by Alberta Health Services (AHS), is using biotricity’s small portable monitors to determine the effectiveness of monitoring heart rate variability (HRV) to predict the onset of illness in intensive care unit (ICU) patients, where patient conditions can change quickly.
Today, the majority of devices that claim to measure heart rate only sample heart rate at intervals, and then produce an average over time. To accurately measure HRV, an electrocardiogram (ECG) is required because this technology is capable of measuring milliseconds between heart beats.
“Most mobile heart rate monitors in use today are extremely inaccurate with a margin of error of up to 40 percent. Because of this, AHS will utilize biotricity’s medical grade, high-resolution ECG and wireless communication capabilities as a perioperative wellness and recovery monitor which we believe will improve outcomes and reduce complications,” said Dr. David Liepert, a University of Calgary professor, anesthesiologist at AHS’ Rockyview General Hospital and lead investigator in the study. “The highly detailed data provided by biotricity’s unique technology is a key factor in our research as it is being used to detect small fluctuations in heart rate, which can indicate the onset of a variety of conditions including cardiovascular disease, stroke, diabetes or sepsis.”
Dr. Liepert research aims to use biotricity’s perioperative wellness monitor in order to follow a patient from pre-surgery, through the procedure, and throughout the recovery process among other uses. The research team believes the monitor could result in a reduction of post-surgery complications including wound infections and blood clots.
“Monitoring a patient during the 30 days after surgery is very important to ensure a patient’s return to full wellness, getting back to normal activity, and getting back to normal life,” said Liepert.
The four-month study, which concludes in April 2016 and is made possible by a grant from the National Research Council of Canada, will track HRV and health outcomes in 20 healthy people and 40 intensive care unit patients.
“I decided to participate in the study because it was a unique opportunity to look at how healthy I actually am,” says Anthony Cook, one of the 20 healthy participants in the study. “I like to consider myself a healthy guy but using this heart rate variability device will provide the data to prove it.”
Government and healthcare organizations are focused on driving costs down by shifting to evidence-based healthcare where individuals, especially those suffering from chronic illnesses, engage in self-management and preventative care.
“Our research with Dr. Liepert will drive the development of our next-generation medical devices that provide more detailed, medical grade data while being easy to wear,” Waqaas Al-Siddiq, founder, president and CEO of Biotricity Inc. “biotricity will disrupt how clinical grade data is captured, used and tracked by both sick and healthy people and will be instrumental in helping health care professionals reduce costs and support the move to evidence-based healthcare.”
TWEET THIS: @biotricity_inc helps scientists uncover link between heart rate ECG and onset of illness #wearables #medicaldevices
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin Chris@mccoinsmith.com 508-429-5988 Richard Smith email@example.com 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. +1(949) 574-3860 BTCY@liolios.com